In 202 frail patients aged 70+ with head and neck cancer, split-course hypofractionated RT gave 35% alive with complete locoregional response at 6 months vs 33% with standard RT (difference +2%, 95% CI -11 to 15; margin 16%). Median survival was 13.0 vs 18.9 months.
RCTn = 202
Ortholan et al. Hypofractionated split-course versus standard radiotherapy in frail older patients with head and neck squamous-cell carcinoma (ELAN-RT trial): a non-inferiority, multicentre, open-label, randomised controlled trial